GSK is set to pay $300 million to license a bispecific antibody from Chimagen Biosciences, aimed at treating autoimmune diseases like lupus. Currently in Phase 1 testing for cancer, the drug targets B cells by engaging T cells, potentially offering a novel therapeutic option for B cell-driven conditions. GSK plans to initiate its own Phase 1 trial next year, pending regulatory approval.
GSK Plc has acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for up to $850 million, enhancing its lupus treatment pipeline. The deal includes a $300 million upfront payment, with Chimagen eligible for up to $550 million in success-based milestones. The antibody drug, currently in early clinical trials for leukemia and lymphoma, is set to enter early trials for lupus in 2025.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
